ribosom
synthes
cyclic
peptid
discov
bacteria
fungi
plant
wide
rang
size
structur
biolog
properti
figur
pharmaceut
industri
gain
interest
peptid
drug
cyclic
peptid
shown
great
potenti
stabil
theta
defensin
known
class
cyclic
peptid
mammal
focu
review
need
understood
broader
context
cyclic
peptid
share
common
featur
challeng
describ
challeng
address
class
cyclic
peptid
might
add
understand
cyclic
peptid
describ
herein
direct
gene
product
note
mani
cyclic
peptid
synthes
exampl
cyclosporin
fungal
peptid
use
immun
also
grow
number
bioactiv
peptid
artifici
cycliz
take
advantag
increas
stabil
afford
cyclic
peptid
backbon
exampl
cycliz
cone
snail
venom
peptid
show
increas
stabil
potenc
anim
pain
cyclic
peptid
discoveri
challeng
lack
termini
make
cyclic
peptid
resist
tradit
sequenc
method
furthermor
unknown
posit
termini
small
size
gene
hamper
search
cyclic
peptid
nucleic
acid
level
howev
new
search
method
develop
particularli
use
mass
data
cyclic
peptid
discov
collect
anticip
new
discoveri
method
develop
class
cyclic
peptid
emerg
novel
bioactiv
applic
cyclic
peptid
produc
typic
compris
amino
acid
first
report
class
ribosom
cyclic
peptid
cyclic
backbon
bacteriocin
elucid
cyclic
bacteriocin
produc
bacteria
phylum
firmicut
globular
structur
compris
cyanobacteria
produc
cyanobactin
contain
posttransl
modif
addit
cyclic
bacteriocin
cyanobactin
seem
produc
defens
compet
bacteria
potenti
applic
antimicrobi
agent
contrast
cyclic
pilin
structur
role
use
transfer
genet
biosynthet
mechan
bacteri
cyclic
peptid
better
understood
eukaryot
counterpart
gene
encod
often
cluster
gene
encod
process
understand
mechan
bacteria
enabl
recombin
cyclic
peptid
product
thu
facilit
develop
cyclic
peptid
therapeut
fungi
amanitacea
famili
produc
two
class
cyclic
peptid
amatoxin
phallocidin
contain
unusu
posttransl
phallocidin
compris
seven
residu
sulfid
link
amatoxin
compris
eight
residu
sulfoxid
link
fungal
cyclic
peptid
flank
pro
residu
process
site
thought
cycliz
prolyl
amatoxin
phallocidin
highli
toxic
human
amatoxin
inhibit
transcript
bind
rna
polymeras
ii
phallocidin
bind
stabil
filament
structur
within
plant
cyclic
peptid
group
three
famili
sunflow
trypsin
cyclotid
compris
approxim
residu
character
cyclic
cystin
knot
follow
discoveri
prototyp
cyclotid
kalata
cyclotid
found
violacea
rubiacea
fabacea
solanacea
cucurbitacea
famili
structur
activ
applic
extens
cyclotid
divid
bracelet
trypsin
inhibitor
subfamili
base
sequenc
although
natur
function
cyclotid
thought
plant
defens
molecul
insect
sever
unrel
pharmacolog
activ
report
activ
membran
bind
appear
mechan
common
exact
mechan
cyclotid
biosynthesi
still
clear
howev
thought
cyclotid
precursor
cleav
n
terminu
asparaginyl
endopeptidas
aep
carri
transpeptid
reaction
form
cyclic
addit
obviou
applic
agricultur
plant
protect
cyclotid
shown
potenti
stabl
scaffold
design
peptid
possibl
develop
includ
product
plant
factori
sunflow
trypsin
inhibitor
smaller
cyclotid
compris
residu
one
disulfid
nucleic
acid
sequenc
encod
sunflow
famili
cyclic
peptid
buri
within
gene
encod
albumin
seed
storag
protein
cycliz
potent
trypsin
inhibitori
activ
sunflow
trypsin
inhibitor
exploit
design
potenti
anticanc
compound
chemic
synthes
analogu
inhibit
proteas
involv
breast
prostat
cancer
respect
recent
report
recommend
name
orbitid
small
cyclic
plant
peptid
earlier
known
cyclolinopeptid
orbitid
compris
five
amino
acid
contrast
cyclotid
high
proport
hydrophob
residu
lack
disulfid
orbitid
discov
ten
plant
famili
cyclotid
natur
function
plant
thought
antiherbivor
antibacteri
agent
although
mani
differ
bioactiv
dna
precursor
orbitid
identifi
saponaria
vaccaria
biosynthesi
appear
involv
cleavag
precursor
oligopeptidas
follow
cycliz
mediat
serin
sinc
discoveri
signific
progress
made
understand
antimicrobi
activ
mani
question
remain
especi
regard
biosynthesi
recent
progress
synthesi
character
facilit
effort
address
unsolv
problem
identifi
new
applic
focu
challeng
opportun
remaind
articl
defensin
peptid
form
part
mammalian
innat
immun
system
provid
defens
microbi
pathogen
regul
immun
compris
amino
acid
contain
three
disulfid
bond
arrang
figur
six
found
human
human
neutrophil
peptid
human
defensin
express
paneth
cell
larger
compris
approxim
amino
acid
three
disulfid
bond
found
human
predominantli
epitheli
cell
male
reproduct
third
class
mammalian
defensin
name
structur
similar
greek
letter
theta
compris
residu
three
disulfid
bond
first
cyclic
mammalian
peptid
rhesu
discov
studi
defensin
express
rhesu
macaqu
macacca
mulata
fraction
screen
leukocyt
extract
result
isol
peptid
potent
antibacteri
activ
sequenc
overlap
fragment
led
elucid
cyclic
backbon
seri
thermolysin
digest
reveal
three
parallel
disulfid
bond
term
cyclic
cystin
search
gene
encod
surprisingli
reveal
two
gene
genbank
encod
fragment
demidefensin
follow
three
residu
stop
codon
figur
gene
pseudogen
name
deft
defensin
theta
gene
respect
gene
appear
truncat
two
encod
splice
togeth
form
cyclic
date
cyclic
peptid
biosynthes
two
separ
gene
unsolv
question
heterodimer
abund
homodimer
isol
homodim
illustr
n
demidefensin
gene
give
rise
third
demidefensin
later
identifi
six
correspond
isol
macaqu
although
amount
peptid
vari
much
factor
three
individu
account
around
total
prefer
heterodimer
speci
homodimer
speci
high
proport
compar
five
variant
might
result
differ
gene
copi
number
differ
express
level
question
remain
address
anoth
major
challeng
understand
gene
human
exist
pseudogen
give
rise
peptid
selst
note
sequenc
similar
gene
encod
gene
encod
human
pseudogen
genbank
contain
stop
codon
signal
sequenc
lehrer
synthes
would
produc
two
transcript
pseudogen
absenc
prematur
stop
peptid
name
retrocyclin
show
potent
activ
low
cytotox
ad
iron
twist
question
human
inherit
intact
less
known
distribut
divers
cyclic
peptid
time
write
review
cyclotid
isol
speci
sinc
elucid
cyclic
structur
differ
isol
three
speci
primat
sinc
discoveri
contrast
might
reflect
rel
difficulti
obtain
primat
tissu
sampl
compar
plant
lack
effici
discoveri
tool
addit
six
isol
rhesu
macaqu
macacca
mulata
four
cdna
identifi
oliv
baboon
papio
anubi
leukocyt
suggest
ten
could
synthes
howev
five
two
peptid
isol
hamadrya
baboon
papio
hamadrya
leukocyt
sequenc
ident
sequenc
date
isol
peptid
level
name
accord
first
letter
speci
primat
found
howev
discov
new
speci
systemat
nomenclatur
need
develop
avoid
ambigu
miss
piec
understand
biosynthesi
lack
knowledg
sequenc
divers
sequenc
known
demidefensin
encod
gene
pseudogen
shown
tabl
isol
peptid
level
contain
six
cystein
residu
howev
interest
pan
troglodyt
pan
paniscu
pseudogen
encod
four
cystein
greatest
sequenc
variat
occur
four
residu
number
arginin
residu
result
charg
contrast
cyclotid
acycl
analogu
report
observ
might
reflect
differ
biosynthet
mechan
cyclotid
distribut
primat
speci
origin
stop
codon
gene
yet
understood
phylogenet
studi
speci
old
new
world
primat
identifi
new
deft
gene
tabl
conclud
silenc
mutat
gene
occur
common
ancestor
human
chimpanze
gorilla
around
million
year
ago
orangutan
lineag
orangutan
pongo
pygmaeu
abelii
intact
silenc
copi
deft
furthermor
stop
codon
appear
arisen
seri
stepwis
mutat
codon
cact
histidin
old
world
monkey
cag
glutamin
orangutan
tag
stop
new
world
accord
role
innat
immun
produc
mainli
bone
express
phagocyt
cell
neutrophil
monocyt
lymphocyt
eosinophil
appear
secret
local
azurophil
howev
express
paneth
cell
crypt
small
intestin
rhesu
macaqu
report
human
express
gene
highest
bone
marrow
also
observ
skelet
muscl
spleen
thymu
inabl
inat
produc
make
human
suscept
hiv
burn
question
difficult
answer
conclus
peptid
found
human
six
gene
human
genom
five
chromosom
gi
upstream
gene
one
chromosom
although
inhibit
two
thai
subtyp
sequenc
deft
gene
persist
seroneg
femal
thailand
show
result
led
conclus
resist
women
due
product
nevertheless
possibl
remain
isol
popul
might
retain
intact
deft
gene
henc
intrins
protect
deft
gene
compris
three
exon
two
intron
figur
exon
encod
propeptid
compris
signal
peptid
proseg
demidefensin
tail
figur
b
although
structur
disulfid
connect
differ
common
featur
precursor
peptid
suggest
similar
process
mechan
might
understand
biosynthet
mechan
challeng
class
cyclic
peptid
much
less
known
biosynthesi
class
cycliz
thought
arisen
separ
differ
kingdom
although
similar
featur
transpeptid
cyclotid
conserv
sequenc
n
termini
cyclotid
propeptid
recogn
aep
proteas
propeptid
thought
cleav
allow
n
terminu
cyclotid
replac
recognit
site
gli
act
nucleophil
cycliz
peptid
similarli
trbc
pilin
bacteria
cleav
cycliz
traf
biosynthesi
also
probabl
involv
proteas
howev
two
new
peptid
bond
need
form
two
peptid
three
disulfid
bond
form
two
demidefensin
build
like
explan
two
form
held
togeth
interchain
disulfid
ligat
figur
c
structur
properti
precursor
might
also
direct
associ
demidefensin
possibl
develop
aris
elucid
biosynthesi
identif
new
cyclic
peptid
insight
peptid
cycliz
arisen
mammal
evid
whether
human
cell
retain
abil
process
demidefensin
transcript
inconclus
two
separ
studi
human
promyelocyt
cell
abl
process
transfect
cdna
one
studi
neither
matur
precursor
studi
presenc
cyclic
retrocyclin
activ
furthermor
latter
studi
aminoglycosid
use
read
stop
codon
human
gene
restor
endogen
express
yeast
screen
use
identifi
protein
interact
defensin
precursor
might
involv
process
stromal
cell
deriv
protein
part
endoplasm
reticulum
chaperon
complex
interact
thu
suggest
might
role
biosynthesi
structur
natur
occur
modifi
determin
nmr
data
give
insight
stabil
mechan
action
structur
three
disulfid
bond
predict
molecular
dynam
later
confirm
nmr
structur
pdb
broaden
nmr
signal
nuclear
overhaus
enhanc
noe
interact
indic
flexibl
figur
structur
synthet
retrocyclin
pdb
determin
presenc
sodium
dodecyl
sulphat
sd
micel
might
stabil
extend
conform
recent
develop
nmr
method
facilit
determin
structur
three
character
cyclic
cystin
ladder
figur
b
pdb
pdb
first
symmetr
pdb
structur
compris
two
highli
constrain
join
turn
heteronuclear
noe
predict
order
paramet
suggest
rigid
previous
sever
structur
avail
protein
data
bank
model
peptid
design
possibl
role
mechan
action
still
unclear
densiti
ultracentrifug
nmr
diffus
measur
suggest
retrocyclin
form
trimer
high
concentr
model
propos
peptid
along
longitudin
axe
disulfid
bond
face
inward
base
select
broaden
cystein
nmr
diffus
measur
support
hypothesi
extend
concentr
rang
suggest
aggreg
state
might
disulfid
connect
cyclic
cystin
ladder
well
establish
confirm
sever
method
comput
method
predict
disulfid
bond
connect
peptid
comparison
structur
possibl
disulfid
connect
calcul
probabl
possibl
disulfid
connect
use
pattern
disulfid
local
constraint
measur
distanc
structur
calcul
without
disulfid
bond
constrain
structur
give
remark
stabil
consist
resist
high
concentr
proteas
inflam
synthet
analogu
vari
number
arrang
disulfid
bond
reveal
depend
structur
stabil
cyclic
cystin
although
analogu
three
two
one
central
disulfid
bond
structur
stabl
lack
disulfid
bond
cyclic
backbon
unstructur
rapidli
degrad
serum
nmr
studi
show
analogu
two
three
disulfid
bond
retain
structur
temperatur
contrast
disulfid
bond
necessari
antibacteri
properti
howev
cyclic
cystin
ladder
might
role
molecular
recognit
antibacteri
activ
physiolog
salt
acycl
analogu
weaker
antibacteri
activ
cyclic
suggest
cyclic
backbon
import
analogu
synthes
even
greater
stabil
show
potent
activ
access
chemic
synthesi
figur
facilit
studi
activ
mechan
earli
synthes
employ
fluorenylmethoxycarbonyl
fmoc
chemistri
assembl
peptid
backbon
peptid
synthesi
spp
follow
oxid
bring
termini
residu
proxim
ligat
use
carbodiimid
edc
hydroxybenzotriazol
hobt
coupl
although
strategi
success
racem
cystein
residu
led
poor
later
studi
three
method
investig
cycliz
oxid
precursor
n
hbtu
n
dipea
dimethylformamid
dmf
tri
dimethyl
amino
phosphonium
hexafluorophosph
bop
dipea
dmf
hobt
edc
dimethylsulfoxid
dmso
mixtur
product
obtain
hbtu
owe
side
reaction
bop
edchobt
gave
desir
major
product
edchobt
method
recommend
eas
challeng
cycliz
larg
overcom
use
nativ
chemic
ligat
nativ
chemic
origin
develop
ligat
two
peptid
chain
also
ideal
synthesi
cyclic
peptid
especi
contain
multipl
cystein
reaction
involv
thioester
exchang
thioester
linker
free
thiol
cystein
residu
format
peptid
bond
achiev
irrevers
acyl
transfer
regener
free
cystein
thiol
figur
inset
sever
nativ
analogu
synthes
use
boc
spp
follow
concurr
cycliz
nativ
chemic
ligat
strategi
also
becom
avail
recent
cycliz
oxid
linear
precursor
lack
effici
vivo
cycliz
method
hinder
recombin
product
sever
semirecombin
approach
report
analogu
contain
three
residu
synthes
use
codon
reprogram
express
peptid
precursor
contain
acid
sequenc
form
diketopiperadin
thioester
rearrang
cycliz
advantag
approach
nonstandard
amino
acid
includ
bacteri
express
system
also
use
produc
precursor
cycliz
either
vitro
vivo
modifi
strategi
open
possibl
produc
cyclic
peptid
librari
peptid
recombinantli
howev
yield
need
improv
mani
analogu
synthes
chemic
studi
mechan
action
optim
antibacteri
antivir
properti
exampl
includ
pseudogen
product
ly
mutant
enabl
label
chromophor
tyr
mutant
enantioanalogu
chemic
synthesi
also
use
produc
simplifi
retrocyclin
analogu
analogu
contain
bioactiv
oxid
unprotect
cystein
residu
appear
give
nativ
ladder
disulfid
nevertheless
one
studi
synthes
use
orthogon
protect
cystein
note
correct
disulfid
pair
assist
format
also
use
illustr
method
synthes
peptid
multipl
disulfid
complex
arrang
without
need
orthogon
protect
disulfid
bond
replac
base
result
analogu
similar
twist
structur
nativ
low
hemolyt
activ
slightli
higher
antibacteri
activ
nativ
antimicrobi
activ
led
initi
discoveri
thought
natur
antimicrobi
advantag
lower
sensit
physiolog
salt
cyclic
backbon
might
role
salt
insensit
acycl
analogu
three
time
less
activ
cyclic
e
coli
contrast
disulfid
bond
essenti
antibacteri
also
bind
neutral
bacteri
toxin
analogu
activ
anthrax
bacilli
spore
bind
anthrax
lethal
howev
acycl
reduc
alkyl
analogu
retrocyclin
lack
activ
suggest
cyclic
backbon
disulfid
bond
role
toxin
furthermor
activ
l
monocytogen
inhibit
listeriolysin
toxin
enabl
bacteria
escap
antifung
activ
c
albican
c
neoforman
v
dahlia
f
oxysporum
also
understand
mechan
antimicrobi
activ
complex
inflammatori
environ
numer
inhibitor
enhanc
present
extrem
antibacteri
activ
thought
caus
interact
membran
glycoprotein
enantiom
similar
antibacteri
illustr
activ
clinic
isol
aureu
p
aeruginosa
might
effect
resist
bacteria
target
cell
membran
rather
specif
differenti
scan
calorimetri
scatter
measur
show
select
anion
membran
zwitterion
membran
indic
posit
charg
face
interact
anion
phospholipid
surfac
plasmon
reson
spr
measur
also
show
higher
affin
anion
membran
zwitterion
membran
number
disulfid
bond
affect
measur
membran
curvatur
scatter
show
gener
neg
curvatur
bacteri
membran
model
indic
potenti
membran
disrupt
depend
composit
cation
amino
orient
circular
dichroism
diffract
lipid
bilay
show
parallel
state
transmembran
state
peptid
howev
transit
two
state
exact
mechan
nmr
measur
indic
adopt
transmembran
orient
dilauroylphosphatidylcholin
dlpc
bilay
orient
thicker
popc
potent
properti
retrocyclin
first
report
cole
therapeut
potenti
gener
much
retrocyclin
inhibit
replic
low
micromolar
concentr
ad
cell
infect
directli
inactiv
viru
prevent
entri
block
fusion
viral
envelop
cell
membran
figur
inhibit
viral
entri
might
mediat
abil
retrocyclin
recogn
bind
sugar
molecul
cell
surfac
fluoresc
label
retrocyclin
analogu
form
patch
surfac
assay
spr
show
bind
repeat
prevent
format
bundl
figur
dock
studi
reveal
glutam
acid
residu
segment
arginin
residu
retrocyclin
might
bind
howev
mutat
residu
lead
resist
retrocyclin
mutat
render
viru
less
recent
studi
effect
hiv
strain
resist
fusion
inhibitor
enfuvirtid
suggest
two
antivir
bind
differ
site
heptad
furthermor
effect
compensatori
mutat
viral
strain
resist
studi
help
guid
develop
fusion
inhibitor
base
import
role
chemistri
elucid
relationship
illustr
varieti
analogu
synthes
exampl
activ
retrocyclin
analogu
develop
replac
anoth
studi
retrocyclin
actual
found
increas
hiv
abil
retrocyclin
inhibit
hiv
entri
depend
hiv
subtyp
possibl
differ
glycoprotein
human
cell
grown
presenc
select
resist
show
decreas
suscept
three
mutat
identifi
resist
virus
envelop
glycoprotein
replac
neg
neutral
residu
posit
charg
also
antiherp
activ
lectin
properti
might
retrocyclin
activ
influenza
viru
bind
surfact
protein
inhibit
viral
entri
immobil
membran
glycoprotein
role
membran
cell
chicken
embryo
transfect
show
reduc
infect
avian
influenza
viru
clear
whether
cell
express
cyclic
chemic
synthes
truncat
analogu
also
shown
furthermor
seri
analogu
inhibit
entri
herp
simplex
viru
cell
bind
surfac
effect
prophylaxi
herp
simplex
viru
type
kerat
mous
obviou
applic
use
antimicrobi
although
antibacteri
activ
compar
antimicrobi
peptid
potent
activ
garner
interest
sever
report
propos
use
retrocyclin
topic
microbicid
reduc
dissolv
polyvinyl
alcohol
film
formul
test
vitro
ex
vivo
safeti
efficaci
vagin
microbicid
stabil
bioavail
test
still
need
carri
recent
report
suggest
could
also
use
immunomodulatori
stimul
adapt
immun
respons
suppress
product
proinflammatori
cytokin
modul
immun
polymicrobi
sepsi
model
mice
dose
lower
level
tumor
necrosi
factor
interleukin
furthermor
system
administ
nontox
stabl
plasma
stimul
immun
respons
adult
earlier
studi
prophylact
treatment
prevent
lethal
infect
mice
strain
sever
acut
respiratori
syndrom
howev
neither
lipopolysaccharid
lp
suggest
immunomodulatori
activ
abil
bind
receptor
help
prevent
viral
furthermor
bind
receptor
plasma
protein
might
concentr
infect
attract
scaffold
peptid
drug
design
constrain
structur
stabil
low
cytotox
inher
concept
prototyp
design
templat
appli
tachyplesin
analogu
similar
rigid
structur
addit
advantag
cyclic
use
scaffold
peptid
drug
cyclic
cystin
ladder
use
constrain
stabil
rgd
sequenc
either
one
show
potent
select
activ
illustr
scaffold
acquir
bioactiv
furthermor
higher
activ
analogu
contain
rgd
loop
suggest
natur
symmetri
might
exploit
design
bifunct
peptid
develop
chemic
synthesi
strategi
analogu
help
drive
applic
drug
scaffold
provid
access
novel
molecul
contain
unnatur
amino
acid
label
mutat
chemic
modif
saw
emerg
new
field
cyclic
peptid
structur
ribosom
origin
cyclic
peptid
bacteria
fungi
plant
elucid
discoveri
reveal
mammal
also
produc
cyclic
peptid
sinc
chemic
tool
discoveri
sequenc
synthesi
structur
determin
facilit
investig
structur
mechan
action
cyclic
peptid
interest
antimicrobi
properti
led
mechanist
insight
discoveri
new
lag
consider
behind
cyclic
peptid
furthermor
biosynthet
mechan
two
separ
gene
product
remain
one
intrigu
yet
elus
question
field
grow
interest
drug
pharmaceut
industri
well
increas
number
valid
target
drug
disrupt
interact
provid
mani
opportun
applic
studi
structur
mechan
action
synthesi
help
promot
develop
therapeut
agent
anticip
next
year
see
discoveri
new
develop
novel
applic
base
favor
chemic
properti
biolog
activ
ann
conibear
complet
bsc
hon
msc
chemistri
rhode
univers
south
africa
current
final
stage
phd
studi
supervis
david
craik
institut
molecular
bioscienc
univers
queensland
australia
phd
research
focus
character
applic
also
interest
applic
nmr
techniqu
chemistri
biolog
publish
receiv
permiss
copyright
owner
includ
object
version
product
pleas
refer
either
publish
onlin
version
product
print
product
one
exist
david
craik
receiv
phd
la
trobe
univers
australia
undertook
postdoctor
research
florida
state
syracus
univers
usa
appoint
head
school
pharmaceut
chemistri
victorian
colleg
pharmaci
melbourn
australia
took
research
appoint
institut
molecular
bioscienc
univers
queensland
research
focus
applic
nmr
spectroscopi
drug
design
develop
publish
receiv
permiss
copyright
owner
includ
object
version
product
pleas
refer
either
publish
onlin
version
product
print
product
one
exist
